Publications by authors named "Jason J Johnson"
Article Synopsis
- A phase II trial was conducted to evaluate the effectiveness of the combination therapy of axitinib (a VEGFR inhibitor) and avelumab (a PD-L1 inhibitor) in patients with recurrent or metastatic adenoid cystic carcinoma (R/M ACC).
- The trial included 40 participants, with 28 being evaluable for efficacy; the objective response rate (ORR) was confirmed at 18%, and median progression-free survival (PFS) was 7.3 months, with median overall survival (OS) at 16.6 months.
- Common treatment-related side effects were fatigue, hypertension, and diarrhea, with a need for dose reductions and treatment discontinuation; further research is needed to assess the benefits of
